The global clinical trial patient recruitment services market size is calculated at USD 1.06 billion in 2025 and is forecasted to reach around USD 2.14 billion by 2034, accelerating at a CAGR of 8.11% from 2025 to 2034. The North America market size surpassed USD 520 million in 2024 and is expanding at a CAGR of 8.16% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Patient Recruitment Services Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Patient Recruitment Services Market, by Service Type
8.1.1. Patient recruitment & registry services
8.1.1.1. Market Revenue and Forecast
8.1.2. Patient retention services
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Clinical Trial Patient Recruitment Services Market, by Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. Clinical Trial Patient Recruitment Services Market, by Therapeutic Area
10.1.1. Respiratory Diseases
10.1.1.1. Market Revenue and Forecast
10.1.2. Pain and Anaesthesia
10.1.2.1. Market Revenue and Forecast
10.1.3. Oncology
10.1.3.1. Market Revenue and Forecast
10.1.4. Central Nervous System
10.1.4.1. Market Revenue and Forecast
10.1.5. Cardiovascular
10.1.5.1. Market Revenue and Forecast
10.1.6. Endocrine
10.1.6.1. Market Revenue and Forecast
10.1.7. Anti-infective
10.1.7.1. Market Revenue and Forecast
10.1.8. Others
10.1.8.1. Market Revenue and Forecast
11.1. Clinical Trial Patient Recruitment Services Market, by Age Group
11.1.1. Child (birth-17 years)
11.1.1.1. Market Revenue and Forecast
11.1.2. Adult (18 - 64 years)
11.1.2.1. Market Revenue and Forecast
11.1.3. Older adults (65 years+)
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service Type
12.1.2. Market Revenue and Forecast, by Phase
12.1.3. Market Revenue and Forecast, by Therapeutic Area
12.1.4. Market Revenue and Forecast, by Age Group
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service Type
12.1.5.2. Market Revenue and Forecast, by Phase
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area
12.1.5.4. Market Revenue and Forecast, by Age Group
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service Type
12.1.6.2. Market Revenue and Forecast, by Phase
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area
12.1.6.4. Market Revenue and Forecast, by Age Group
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service Type
12.2.2. Market Revenue and Forecast, by Phase
12.2.3. Market Revenue and Forecast, by Therapeutic Area
12.2.4. Market Revenue and Forecast, by Age Group
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service Type
12.2.5.2. Market Revenue and Forecast, by Phase
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area
12.2.5.4. Market Revenue and Forecast, by Age Group
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service Type
12.2.6.2. Market Revenue and Forecast, by Phase
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area
12.2.6.4. Market Revenue and Forecast, by Age Group
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service Type
12.2.7.2. Market Revenue and Forecast, by Phase
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area
12.2.7.4. Market Revenue and Forecast, by Age Group
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service Type
12.2.8.2. Market Revenue and Forecast, by Phase
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area
12.2.8.4. Market Revenue and Forecast, by Age Group
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service Type
12.3.2. Market Revenue and Forecast, by Phase
12.3.3. Market Revenue and Forecast, by Therapeutic Area
12.3.4. Market Revenue and Forecast, by Age Group
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service Type
12.3.5.2. Market Revenue and Forecast, by Phase
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area
12.3.5.4. Market Revenue and Forecast, by Age Group
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service Type
12.3.6.2. Market Revenue and Forecast, by Phase
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area
12.3.6.4. Market Revenue and Forecast, by Age Group
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service Type
12.3.7.2. Market Revenue and Forecast, by Phase
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area
12.3.7.4. Market Revenue and Forecast, by Age Group
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service Type
12.3.8.2. Market Revenue and Forecast, by Phase
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area
12.3.8.4. Market Revenue and Forecast, by Age Group
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service Type
12.4.2. Market Revenue and Forecast, by Phase
12.4.3. Market Revenue and Forecast, by Therapeutic Area
12.4.4. Market Revenue and Forecast, by Age Group
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service Type
12.4.5.2. Market Revenue and Forecast, by Phase
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area
12.4.5.4. Market Revenue and Forecast, by Age Group
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service Type
12.4.6.2. Market Revenue and Forecast, by Phase
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area
12.4.6.4. Market Revenue and Forecast, by Age Group
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service Type
12.4.7.2. Market Revenue and Forecast, by Phase
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area
12.4.7.4. Market Revenue and Forecast, by Age Group
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service Type
12.4.8.2. Market Revenue and Forecast, by Phase
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area
12.4.8.4. Market Revenue and Forecast, by Age Group
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service Type
12.5.2. Market Revenue and Forecast, by Phase
12.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.4. Market Revenue and Forecast, by Age Group
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service Type
12.5.5.2. Market Revenue and Forecast, by Phase
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.5.4. Market Revenue and Forecast, by Age Group
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service Type
12.5.6.2. Market Revenue and Forecast, by Phase
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area
12.5.6.4. Market Revenue and Forecast, by Age Group
13.1. IQVIA; Inc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Antidote
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. BBK Worldwide
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Clara Health
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Clariness
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Clinical Site Services (CCSi)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Worldwide Clinical Trials
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Thermo Fisher Scientific Inc. (PPD Inc.)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Veristat
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Elligo Health Research
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample